CG Oncology, Inc. Common stock (CGON) financial statements and ratios from SEC XBRL: revenue $4.04M (TTM), net margin -3985.0%, revenue growth 254.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $4.04M |
| Net Margin | -3985.0% |
| Revenue Growth (YoY) | 254.7% |
| EPS Growth (YoY) | 47.5% |
| FCF Growth (YoY) | 67.8% |
| Price / Book | 6.69 |
| Price / Sales | 1379.26 |
| FCF Yield | -4.6% |
| Altman Z-Score | 100.51 (safe) |
| Sector P/E (Healthcare) | 21.6 |
CGON overview · CGON earnings · CGON KPIs · CGON investor relations · CGON ownership · CGON peers · CGON filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.